Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2020

View Archived Issues

Copper escort alleviates Menkes disease

Immunity-related pathways contribute to the genetic burden of asthma pathology, new GWAS shows

Phase I data presented for LC51-0255

TBR-760 results in complete arrested tumor growth in mouse model of NFPA

Discovery of potent BACE1 inhibitor, AM-6494

First patient dosed in phase I/II study of TJD5 in China

Sunovion discontinues development of dasotraline

New androgen receptor antagonists described by ESSA Pharma

Enrollment of first patient in phase III study of viltolarsen in boys with DMD

Insilico Medicine Hong Kong discovers DDR1 inhibitors

Ascletis receives IND approval in China for clinical development of ASC-41 in NASH

Nurix Therapeutics patents Bruton tyrosine kinase-degrading compounds

ViiV Healthcare discovers new HIV-1 Capsid protein p24 assembly inhibitors

New adenosine A2A and A2B receptors disclosed by Merck KGaA

miRNA-126-5p circulating levels are decreased in severe sepsis

Improved therapeutic index could reduce opioid toxicity

Blueprint Medicines' BLU-847 shows activity against wild-type and mutant tyrosine kinase receptors

Immunic receives approval to begin phase II study of IMU-838 for COVID-19

SHISA4 expression proven useful to monitor nintedanib therapy in patients with IPF

Merck & Co. reports phase II data on MK-6482 for VHL disease-associated ccRCC

Vyriad opens phase II trial of Voyager-V1 in combination with cemiplimab for cancer

Viela reports interim phase Ib data on VIB-7734 in cutaneous lupus erythematosus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...